Summary report of the Standards, Options and Recommendations for the use of serum tumour markers in breast cancer: 2000.
作者信息
Basuyau J P, Blanc-Vincent M P, Bidart J M, Daver A, Deneux L, Eche N, Gory-Delabaere G, Pichon M F, Riedinger J M
机构信息
Centre Henri Becquerel, Rouen, France.
出版信息
Br J Cancer. 2003 Aug;89 Suppl 1(Suppl 1):S32-4. doi: 10.1038/sj.bjc.6601082.
Abstract
摘要
相似文献
1
Summary report of the Standards, Options and Recommendations for the use of serum tumour markers in breast cancer: 2000.《乳腺癌血清肿瘤标志物应用的标准、选择及建议：2000年总结报告》
Br J Cancer. 2003 Aug;89 Suppl 1(Suppl 1):S32-4. doi: 10.1038/sj.bjc.6601082.
2
[Standards, Options and Recommendations (SOR) for tumor markers in breast cancer. SOR Working Group].[乳腺癌肿瘤标志物的标准、选项及建议（SOR）。SOR工作组]
Bull Cancer. 2000 Oct;87(10):723-37.
3
Sensitivity of CA 15-3, CEA and serum HER2 in the early detection of recurrence of breast cancer.CA 15-3、CEA 和血清 HER2 在乳腺癌早期复发检测中的敏感性。
Clin Chem Lab Med. 2013 Jul;51(7):1511-9. doi: 10.1515/cclm-2012-0488.
4
Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).血清细胞角蛋白片段21.1（CYFRA 21.1）作为乳腺癌肿瘤标志物：与糖类抗原15.3（CA 15.3）和癌胚抗原（CEA）的比较
Clin Chem Lab Med. 2002 Mar;40(3):298-303. doi: 10.1515/CCLM.2002.047.
5
The follow-up of women at high risk for breast cancer relapse.乳腺癌复发高危女性的随访。
Breast. 2009 Oct;18 Suppl 3:S74-7. doi: 10.1016/S0960-9776(09)70277-2.
6
Postoperative follow-up of patients with early breast cancer: reappraisal of serum tumor markers.
Surg Today. 2002;32(1):13-8. doi: 10.1007/s595-002-8106-5.
7
Paired measurement of serum amyloid A (SAA) and paraoxonase 1 (PON1) as useful markers in breast cancer recurrence.配对检测血清淀粉样蛋白A（SAA）和对氧磷酶1（PON1）作为乳腺癌复发的有用标志物。
Clin Biochem. 2015 Nov;48(16-17):1181-3. doi: 10.1016/j.clinbiochem.2015.07.020. Epub 2015 Jul 17.
8
An individual reference limit for 'early' diagnosis of metastatic breast cancer during postoperative follow-up.术后随访期间转移性乳腺癌“早期”诊断的个体参考限值。
Biomark Med. 2015;9(4):307-17. doi: 10.2217/bmm.15.6.
9
10
Serum c-erbB-2 protein is a useful marker for monitoring tumor recurrence of the breast.血清c-erbB-2蛋白是监测乳腺癌肿瘤复发的有用标志物。
Int J Cancer. 2007 Jan 15;120(2):357-61. doi: 10.1002/ijc.22166.
引用本文的文献
1
Exploring the Prognostic Value of CS15-3 Tumor Marker in Breast Cancer Recurrence.探讨 CS15-3 肿瘤标志物在乳腺癌复发中的预后价值。
Asian Pac J Cancer Prev. 2024 Jan 1;25(1):229-232. doi: 10.31557/APJCP.2024.25.1.229.
2
Autoantibodies to tailor-made panels of tumor-associated antigens in breast carcinoma.乳腺癌中针对肿瘤相关抗原定制面板的自身抗体。
J Oncol. 2011;2011:982425. doi: 10.1155/2011/982425. Epub 2011 Mar 3.
3
Autoantibodies to tumor-associated antigens in breast carcinoma.乳腺癌相关肿瘤抗原的自身抗体。
J Oncol. 2010;2010:264926. doi: 10.1155/2010/264926. Epub 2010 Nov 21.
4
Circulating tumour markers in breast cancer.乳腺癌中的循环肿瘤标志物
Eur J Nucl Med Mol Imaging. 2004 Jun;31 Suppl 1:S15-22. doi: 10.1007/s00259-004-1523-z. Epub 2004 May 4.
本文引用的文献
1
SOR: project methodology.SOR：项目方法学。
Br J Cancer. 2001 May;84 Suppl 2(Suppl 2):8-16. doi: 10.1054/bjoc.2000.1757.
2
2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology.2000年乳腺癌和结直肠癌肿瘤标志物使用建议更新：美国临床肿瘤学会临床实践指南
J Clin Oncol. 2001 Mar 15;19(6):1865-78. doi: 10.1200/JCO.2001.19.6.1865.
3
[Standards, Options and Recommendations (SOR) for tumor markers in breast cancer. SOR Working Group].[乳腺癌肿瘤标志物的标准、选项及建议（SOR）。SOR工作组]
Bull Cancer. 2000 Oct;87(10):723-37.
4
Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology.乳腺癌和结直肠癌肿瘤标志物应用的临床实践指南。1996年5月17日由美国临床肿瘤学会采用。
J Clin Oncol. 1996 Oct;14(10):2843-77. doi: 10.1200/JCO.1996.14.10.2843.
5
Working Group on Tumor Marker Criteria (WGTMC).
Tumour Biol. 1990;11(5):287-8. doi: 10.1159/000217662.
Zotero 插件